KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Medicines and Healthcare products Regulatory Agency ...

HAE attacks can now be treated with a pill, Ekterly (sebetralstat), instead by injection or infusion. That could translate to faster symptom relief.

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 15 July 2025, approved sebetralstat (Ekterly) for ...

The MHRA has approved sebetralstat (Ekterly) as the first oral, on-demand treatment for hereditary angioedema (HAE) attacks ...

For the second time in under 3 weeks, the FDA has approved a treatment for the inherited genetic disorder characterized by recurrent episodes of severe swelling.

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today approved Ekterly (sebetralstat) 0for the ...

The FDA signed off on KalVista Pharmaceuticals' emergency treatment for swelling attacks associated with a rare, genetic ...

Sebetralstat, if approved, would be the first oral on-demand treatment for HAE attacks, with the potential to address some of the most significant unmet needs in HAE and become the foundational ...

SAN DIEGO — Patients with hereditary angioedema whose attacks impacted their larynx experienced on-demand relief within 1.29 hours with oral sebetralstat, preventing potentially fatal outcomes ...

Sebetralstat was reported to have a similar safety profile to placebo, with adverse events occurring in 2.3%, 2.2%, and 4.8% of the 300mg, 600mg, and placebo groups, respectively.

– Submissions support KalVista’s mission of building a global footprint for sebetralstat to address the significant unmet need for people with HAE worldwide – – If approved, sebetralstat ...

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has approved ...